Skip to content

Study of serum interleukin 17 level in children with bronchial asthma

Study of serum interleukin 17 level in children with bronchial asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201602001487159
Enrollment
85
Registered
2016-02-23
Start date
2015-01-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Paediatrics

Interventions

asthmatic group
control

Sponsors

mohammed sami bazzari
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Every Asthmatic child had at least three attacks of (paroxysmal dyspnea, cough, and wheeze). Attack was relived spontaneously or with treatment (mainly with beta 2 agonist). Patients had to be completely symptoms free for at least 2 weeks in between attacks. Asthmatic children had to fulfill the criteria of asthmatic diagnosis of GINA guidelines (2014) [6].

Exclusion criteria

Exclusion criteria: Any patient had been used systemic corticosteroid in order not to affect Interleukin 17 serum level. Patients were diagnosed with any of Asthma differential diagnoses diseases Patients were known as a carrier of a blood transmitted infectious disease or had suffered from conditions in which phlebotomy was contraindicated.

Design outcomes

Primary

MeasureTime frame
There was a highly significant difference in serum levels of IL-17 and total IgE in asthmatic than in control groups in children.

Secondary

MeasureTime frame
There was also insignificant positive correlation between IL-17and IgE

Countries

Egypt

Contacts

Public Contactmohammed bazzari
msbazzari@gmail.com01005033347

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026